False-positive results of the determination of bacterial endotoxins in drugs: the use of a β-glucan blocker
- 作者: Shapovalova O.V.1, Neugodova N.P.1, Sapozhnikova G.A.1
-
隶属关系:
- Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation
- 期: 卷 69, 编号 1 (2020)
- 页面: 5-9
- 栏目: Articles
- URL: https://journals.eco-vector.com/0367-3014/article/view/113275
- DOI: https://doi.org/10.29296/25419218-2020-01-01
- ID: 113275
如何引用文章
详细
Introduction. Assessment of the quality of drugs in terms of the indicator «Bacterial Endotoxins» has shown that along with the latter, β-glucans undergo enzymatic reaction with amebocyte lysate. This leads to false positive results in the (Limulus amebocyte lysate) LAL test, which poses a serious problem in the determination of pyrogenic impurities. There are 2 main sources of β-glucans in drugs: 1) excipients in the composition of a drug (for example, carmellose sodium, crosslinked sodium carboxymethylcellulose) and 2) technological impurities of the active ingredient at the drug production stage. Objective: to investigate the potentiating (reinforcing) effect of β-glucans in tests for bacterial endotoxins, to search and select a method for its elimination. Material and methods. The investigation objects were agents: Betamethasone, injectable suspension (7 mg/ml), and Inosine, injectable solution (20 mg/ml). Endotoxin-specific buffer (β-glucan blocker) was used to carry out the LAL test in gel-clot and chromogenic kinetic modifications. Results. The investigators considered the main causes of false results: potentiation (reinforcement) of a reaction of the LAL reagent with bacterial endotoxins due to the presence of β-glucans in the agents. Procedures were developed to eliminate the factors interfering with the LAL test in order to avoid false-positive results. Conclusion. Methodological approaches were elaborated to prevent the influence of a potentiating (reinforcing) interfering factor on the results of the LAL test
全文:

作者简介
Olga Shapovalova
Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation
Email: shapovalova@expmed.ru
Natalia Neugodova
Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation
Email: neugodova@expmed.ru
Galina Sapozhnikova
Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation
Email: sapozhnikova@expmed.ru
参考
- Bohn J.A., BeMiHe J.N. (1->3)-p-d-Glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydrate Polymers, 1995; 28(1): 3-14.
- FinkelmanM.(1,3)-|3-D-Glucan: Biological Properties and Implications for LAL Testing LAL UPDATE, 2005; 22 (2): 1 - 6.
- Sandle T. Pharmaceutical product impurities: considering beta glucans. [Electronic resource] Access mode: http://www. americanpharmaceuticalreview.com/Featured-Articles/152953-Pharmaceutical-Product-Impurities-Considering-Beta-Glucans/
- Williams K. Endotoxins Pyrogens, LAL Testing and Depyrogenation third Edition (Drugs and the Pharmaceutical Sciences), 2007: 198.
- Barton C., Vigor K., Scott R., Jones P.,Lentfer H., Bax H., Josephs D., Karagiannis S., Spicer J.Beta-glucan contamination of pharmaceutical products: How much should we accept? [Electronic resource] Access mode:https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC5069311/#
- Жилякова Е.Т., Попов Н.Н., Новикова М.Ю., Новиков О.О., Халикова М.А., Казакова В.С. Изучение физикохимических и технологических характеристик натрий карбоксиметилцеллюлозы с целью создания пролонгированных лекарственных форм с жидкой дисперсионной средой. [Электронный ресурс]. Режим доступа: http:// dspace.bsu.edu.ru/bit-stream/123456789/12393/1/Zhilyakova_Izuchen_Fiziko.pdf.
- Белясова Н.А. Микробиология. Минск: Высшая школа, 2012: 246. [Belyasova N. Microbiology. Minsk: Enter. SHK., 2012: 246 (in Russian)].
- Dobrovolskaia M. A., Neil S. Handbook of Immunological Properties of Engineered Nanomaterials. Vol. 1, 2013: 86 - 87.
- Государственная фармакопея Российской Федерации XIII изд., 2015: 956 - 973. [State Pharmacopoeia of the Russian Federation XIII ed., 2015: 956-73 (in Russian)].
补充文件
